Cargando…

Immune Response, Safety, and Survival and Quality of Life Outcomes for Advanced Colorectal Cancer Patients Treated with Dendritic Cell Vaccine and Cytokine-Induced Killer Cell Therapy

Purpose. To determine the immune response after dendritic cell (DC) vaccine and cytokine-induced killer cells (CIK) therapy and assess its associated toxicity, survival benefit, and changes in the quality of life (QOL) of advanced colorectal cancer (CRC) patients. Methods. We recruited 100 patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Hui, Yang, Xuejing, Li, Jiali, Ren, Yanjie, Zhang, Tianyu, Zhang, Chunze, Zhang, Jintai, Li, Jing, Pang, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4124766/
https://www.ncbi.nlm.nih.gov/pubmed/25136601
http://dx.doi.org/10.1155/2014/603871
_version_ 1782329669995986944
author Zhu, Hui
Yang, Xuejing
Li, Jiali
Ren, Yanjie
Zhang, Tianyu
Zhang, Chunze
Zhang, Jintai
Li, Jing
Pang, Yan
author_facet Zhu, Hui
Yang, Xuejing
Li, Jiali
Ren, Yanjie
Zhang, Tianyu
Zhang, Chunze
Zhang, Jintai
Li, Jing
Pang, Yan
author_sort Zhu, Hui
collection PubMed
description Purpose. To determine the immune response after dendritic cell (DC) vaccine and cytokine-induced killer cells (CIK) therapy and assess its associated toxicity, survival benefit, and changes in the quality of life (QOL) of advanced colorectal cancer (CRC) patients. Methods. We recruited 100 patients with unresectable CRC orrelapsed CRC after surgery who received DC vaccine and CIK cells (group immunotherapy, group I), and, as a control, 251 patients who had similar characteristics and underwent similar treatments, except for this immunotherapy (group nonimmunotherapy, group NI). After a follow-up period of 489.2 ± 160.4 days, overall survival (OS) of the two groups was compared using the Kaplan-Meier method. Results. In group I, 62% of patients developed a positive delayed type hypersensitivity response, and most patients showed an improvement in physical strength (75.2%), appetite (74.2%), sleeping (72.1%), and body weight (70.1%). Adverse events were fever (29.5%), insomnia (19.2%), anorexia (9.1%), sore joints (5.4%), and skin rash (1.0%). No toxicity was observed in patients treated with DC vaccine and CIK therapy. OS was significantly longer in group I than in group NI (P = 0.043). Conclusion. DC vaccine and CIK therapy were safe and could induce an immune response against CRC, thereby improving QOL and prolonging OS.
format Online
Article
Text
id pubmed-4124766
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-41247662014-08-18 Immune Response, Safety, and Survival and Quality of Life Outcomes for Advanced Colorectal Cancer Patients Treated with Dendritic Cell Vaccine and Cytokine-Induced Killer Cell Therapy Zhu, Hui Yang, Xuejing Li, Jiali Ren, Yanjie Zhang, Tianyu Zhang, Chunze Zhang, Jintai Li, Jing Pang, Yan Biomed Res Int Clinical Study Purpose. To determine the immune response after dendritic cell (DC) vaccine and cytokine-induced killer cells (CIK) therapy and assess its associated toxicity, survival benefit, and changes in the quality of life (QOL) of advanced colorectal cancer (CRC) patients. Methods. We recruited 100 patients with unresectable CRC orrelapsed CRC after surgery who received DC vaccine and CIK cells (group immunotherapy, group I), and, as a control, 251 patients who had similar characteristics and underwent similar treatments, except for this immunotherapy (group nonimmunotherapy, group NI). After a follow-up period of 489.2 ± 160.4 days, overall survival (OS) of the two groups was compared using the Kaplan-Meier method. Results. In group I, 62% of patients developed a positive delayed type hypersensitivity response, and most patients showed an improvement in physical strength (75.2%), appetite (74.2%), sleeping (72.1%), and body weight (70.1%). Adverse events were fever (29.5%), insomnia (19.2%), anorexia (9.1%), sore joints (5.4%), and skin rash (1.0%). No toxicity was observed in patients treated with DC vaccine and CIK therapy. OS was significantly longer in group I than in group NI (P = 0.043). Conclusion. DC vaccine and CIK therapy were safe and could induce an immune response against CRC, thereby improving QOL and prolonging OS. Hindawi Publishing Corporation 2014 2014-07-17 /pmc/articles/PMC4124766/ /pubmed/25136601 http://dx.doi.org/10.1155/2014/603871 Text en Copyright © 2014 Hui Zhu et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Zhu, Hui
Yang, Xuejing
Li, Jiali
Ren, Yanjie
Zhang, Tianyu
Zhang, Chunze
Zhang, Jintai
Li, Jing
Pang, Yan
Immune Response, Safety, and Survival and Quality of Life Outcomes for Advanced Colorectal Cancer Patients Treated with Dendritic Cell Vaccine and Cytokine-Induced Killer Cell Therapy
title Immune Response, Safety, and Survival and Quality of Life Outcomes for Advanced Colorectal Cancer Patients Treated with Dendritic Cell Vaccine and Cytokine-Induced Killer Cell Therapy
title_full Immune Response, Safety, and Survival and Quality of Life Outcomes for Advanced Colorectal Cancer Patients Treated with Dendritic Cell Vaccine and Cytokine-Induced Killer Cell Therapy
title_fullStr Immune Response, Safety, and Survival and Quality of Life Outcomes for Advanced Colorectal Cancer Patients Treated with Dendritic Cell Vaccine and Cytokine-Induced Killer Cell Therapy
title_full_unstemmed Immune Response, Safety, and Survival and Quality of Life Outcomes for Advanced Colorectal Cancer Patients Treated with Dendritic Cell Vaccine and Cytokine-Induced Killer Cell Therapy
title_short Immune Response, Safety, and Survival and Quality of Life Outcomes for Advanced Colorectal Cancer Patients Treated with Dendritic Cell Vaccine and Cytokine-Induced Killer Cell Therapy
title_sort immune response, safety, and survival and quality of life outcomes for advanced colorectal cancer patients treated with dendritic cell vaccine and cytokine-induced killer cell therapy
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4124766/
https://www.ncbi.nlm.nih.gov/pubmed/25136601
http://dx.doi.org/10.1155/2014/603871
work_keys_str_mv AT zhuhui immuneresponsesafetyandsurvivalandqualityoflifeoutcomesforadvancedcolorectalcancerpatientstreatedwithdendriticcellvaccineandcytokineinducedkillercelltherapy
AT yangxuejing immuneresponsesafetyandsurvivalandqualityoflifeoutcomesforadvancedcolorectalcancerpatientstreatedwithdendriticcellvaccineandcytokineinducedkillercelltherapy
AT lijiali immuneresponsesafetyandsurvivalandqualityoflifeoutcomesforadvancedcolorectalcancerpatientstreatedwithdendriticcellvaccineandcytokineinducedkillercelltherapy
AT renyanjie immuneresponsesafetyandsurvivalandqualityoflifeoutcomesforadvancedcolorectalcancerpatientstreatedwithdendriticcellvaccineandcytokineinducedkillercelltherapy
AT zhangtianyu immuneresponsesafetyandsurvivalandqualityoflifeoutcomesforadvancedcolorectalcancerpatientstreatedwithdendriticcellvaccineandcytokineinducedkillercelltherapy
AT zhangchunze immuneresponsesafetyandsurvivalandqualityoflifeoutcomesforadvancedcolorectalcancerpatientstreatedwithdendriticcellvaccineandcytokineinducedkillercelltherapy
AT zhangjintai immuneresponsesafetyandsurvivalandqualityoflifeoutcomesforadvancedcolorectalcancerpatientstreatedwithdendriticcellvaccineandcytokineinducedkillercelltherapy
AT lijing immuneresponsesafetyandsurvivalandqualityoflifeoutcomesforadvancedcolorectalcancerpatientstreatedwithdendriticcellvaccineandcytokineinducedkillercelltherapy
AT pangyan immuneresponsesafetyandsurvivalandqualityoflifeoutcomesforadvancedcolorectalcancerpatientstreatedwithdendriticcellvaccineandcytokineinducedkillercelltherapy